Cardiovascular effects of neuregulin-1/erbB signaling: Role in vascular signaling and angiogenesis

Current Pharmaceutical Design

Volumn 20, Issue 30, 2014, Pages 4899-4905

  Hedhli, Nadia ^a   Kalinowski, April ^a   Russell, Kerry S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; Endothelial cells; Erbb; Heart failure; Neuregulin; Smooth muscle cells; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; INTEGRIN; NEU DIFFERENTIATION FACTOR; VASCULOTROPIN; EGFR PROTEIN, HUMAN; NRG1 PROTEIN, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; AUTOCRINE EFFECT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; GENE ACTIVATION; GENE INACTIVATION; HEART DEVELOPMENT; HEART MUSCLE CELL; HEART PRESERVATION; HEART PROTECTION; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TISSUE STRUCTURE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ARTICLE; ENZYME ACTIVATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906234368     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131125151058     Document Type: Review

References (79)

1. Schubert D, Heinemann S, Carlisle W, et al. Clonal cell lines from the rat central nervous system. Nature 1974; 249: 224-227.
2. Padhy LC, Shih C, Cowing D, et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982; 28: 865-871.
3. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbb-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
4. Bargmann C, Hung M, Weinberg R. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230.
5. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease. J Clin Oncol 1987; 5: 999-1006.
6. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the her- 2/neu oncogene. Science 1987; 235: 177-182.
7. Hedhli N, Russell K. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev 2011; 7: 221-233.
8. Negro A, Brar BK, Lee KF. Essential roles of her2/erbb2 in cardiac development and function. Recent Prog Horm Res 2004; 59: 1-12.
9. Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving transtuzumab (herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 1999; 26: 96-101.
10. Chien K. Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Sem Oncol 2000; 27: 9-14.
11. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. Semin Oncol 2002; 29: 22-28.
12. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-3865.
13. Lemke GE, Brockes JP. Identification and purification of glial growth factor. J Neurosci 1984; 4: 75-83.
14. Brockes JP, Lemke GE, Balzer DR, Jr. Purification and preliminary characterization of a glial growth factor from the bovine pituitary. J Biol Chem 1980; 255: 8374-8377.
15. Falls DL. Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
16. Jones J, Akita R, Sliwkowski M. Binding specificities and affinities of egf domains for erbb receptors. FEBS Lett 1999; 447: 227-231.
17. Riese D, van Raaij T, Plowman G, et al. The cellular response to neuregulins is governed by complex interactions of the erbb receptor family. Mol Cell Biol 1995; 15: 5770-5776.
18. Chang H, Riese D, Gilbert W, et al. Ligands for erbb-family receptor encoded by a neuregulin-like gene. Nature 1997; 387: 509-512.
19. Carraway K, Weber J, Unger M, et al. Neuregulin-2, a new ligand of erbb3/erbb4-receptor tyrosine kinases. Nature 1997; 387: 512-516.
20. Higashiyama S, Horikawa M, Yamada K, et al. A novel brain-derived member of the epidermal growth factor family that interacts with erbb3 and erbb4. J Biochem 1997; 122: 675-680.
21. Zhang D, Sliwkowski M, Mark M, et al. Neuregulin-3 (nrg3): A novel neural tissue-enriched protein that binds and activates erbb4. Proc Natl Acad Sci USA 1997; 94: 9562-9567.
22. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: A novel growth factor that acts through the erbb-4 receptor tyrosine kinase. Oncogene 1999; 18: 2681-2689.
23. Pinkas-Kramarski R, Shelly M, Guarino B, et al. Erbb tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998; 18: 6090-6101.
24. Garrett TP, McKern NM, Lou M, et al. The crystal structure of a truncated erbb2 ectodomain reveals an active conformation, poised to interact with other erbb receptors. Mol Cell 2003; 11: 495-505.
25. Lee K, Simon H, Chen H, et al. Requirement for neuregulin receptor erbb2 in neural and cardiac development. Nature 1995; 378: 394-398.
26. Riese DI, Stern D. Specificity within the egf family/erbb receptor signaling network. BioEssays 1998; 20: 41-48.
27. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of erbb2 and erbb4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-10269.
28. Hedhli N, Huang Q, Kalinowski A, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation 2011; 123: 2254-2262.
29. Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbb2 and erbb4 in failing human myocardium - depressed expression and attenuated activation. Basic Res Cardiol 2005; 100: 240-249.
30. Russell KS, Stern DF, Polverini PJ, et al. Neuregulin activation of erbb receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999; 277: H2205-H2211.
31. Fukazawa R, Ogawa S, Frantz S, et al. Differential signaling by epidermal growth factor and neuregulin in rat cardiac myocytes and cardiac microvascular endothelial cells (abstract). Circulation 2000; 102: 2-138.
32. Garratt AN, Ozcelik C, Birchmeier C. Erbb2 pathways in heart and neural diseases. Trends Cardiovasc Med 2003; 13: 80-86.
33. Kalinowski A, Hedhli N, Russell KS. Vascular smooth muscle cells express erbb receptors and migrate in response to neuregulin. Circulation 2009; 120: S1168b.
34. Gassman M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the erbb4 neuregulin receptor. Nature 1995; 378: 390-394.
35. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
36. Erickson S, O'Shea K, Ghaboosi N, et al. Erbb3 is required for normal cerebellar and cardiac development: A comparison with erbb2- and heregulin-deficient mice. Development 1997; 124: 4999-5011.
37. Camenisch TD, Schroeder JA, Bradley J, et al. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of erbb2-erbb3 receptors. Nat Med 2002; 8: 850-855.
38. Rentschler S, Zander J, Meyers K, et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci USA 2002; 99: 10464-10469.
39. Uray IP, Connelly JH, Thomazy V, et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 2002; 21: 771-782.
40. Ky B, Kimmel SE, Safa RN, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009; 120: 310-317.
41. DeBeradinis B, Januzzi JL, Jr. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol 2012; 27: 661-668.
42. Gassanov N, Biesenbach E, Caglayan E, et al. Natriuretic peptides in therapy for decompensated heart failure. European journal of clinical pharmacology 2012; 68: 223-230.
43. Hintsanen M, Elovainio M, Puttonen S, et al. Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med 2007; 33: 148-155.
44. Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis 2011; 22: 577-582.
45. Clement CM, Thomas LK, Mou Y, et al. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res 2007; 44: 303-312.
46. Xu G, Watanabe T, Iso Y, et al. Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009; 105: 500-510.
47. Brutsaert DL. Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003; 83: 59-115.
48. Shah AM, Grocott-Mason RM, Pepper CB, et al. The cardiac endothelium: Cardioactive mediators. Prog Cardiovasc Dis 1996; 39: 263-284.
49. Li K, Rouleau JL, Andries LJ, et al. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 1993; 72: 768-777.
50. Hoenig MR, Bianchi C, Rosenzweig A, et al. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol 2008; 6: 292-300.
51. Hedhli N, Russell KS. Cytostatic drugs, neuregulin activation of erbb receptors, and angiogenesis. Curr Hypertens Rep 2010; 12: 411-417.
52. Pentassuglia L, Sawyer DB. The role of neuregulin-1beta/erbb signaling in the heart. Exp Cell Res 2009; 315: 627-637.
53. Bersell K, Arab S, Haring B, et al. Neuregulin1/erbb4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009; 138: 257-270.
54. Chaudhry HW, Dashoush NH, Tang H, et al. Cyclin a2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem 2004; 279: 35858-35866.
55. Wadugu B, Kuhn B. The role of neuregulin/erbb2/erbb4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 2012; 302: H2139-H2147.
56. Fukazawa R, Miller TA, Kuramochi Y, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbb4-dependent activation of pi3-kinase/akt. J Mol Cell Cardiol 2003; 35: 1473-1479.
57. Kalinowski A, Plowes NJ, Huang Q, et al. Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. Faseb J 2010; 24: 2567-2575.
58. Guler M, Yilmaz T, Ozercan I, et al. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009; 147: 703-708e2.
59. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbb-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006; 48: 1438-1447.
60. Hedhli N, Dobrucki LW, Kalinowski A, et al. Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. Cardiovasc Res 2012; 93: 516-524.
61. Somanath PR, Ciocea A, Byzova TV. Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 2009; 53: 53-64.
62. Haenssen KK, Caldwell SA, Shahriari KS, et al. Erbb2 requires integrin alpha5 for anoikis resistance via src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123: 1373-1382.
63. Wang H, Leavitt L, Ramaswamy R, et al. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: Regulation of erbb2-mediated integrin activation. J Biol Chem 2010; 285: 13569-13579.
64. Ieguchi K, Fujita M, Ma Z, et al. Direct binding of the egf-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/erbb signaling. J Biol Chem 2010; 285: 31388-31398.
65. Somanath PR, Malinin NL, Byzova TV. Cooperation between integrin alphavbeta3 and vegfr2 in angiogenesis. Angiogenesis 2009; 12: 177-185.
66. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, et al. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000; 275: 39451-39457.
67. Laughner E, Taghavi P, Chiles K, et al. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: Novel mechanism for hif-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
68. Tsai PW, Shiah SG, Lin MT, et al. Up-regulation of vascular endothelial growth factor c in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa b signaling pathway. J Biol Chem 2003; 278: 5750-5759.
69. Iivanainen E, Paatero I, Heikkinen SM, et al. Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 2007; 313: 2896-2909.
70. Nakaoka Y, Nishida K, Narimatsu M, et al. Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/erbb signaling. J Clin Invest 2007; 117: 1771-1781.
71. Sabri A, Samuel JL, Marotte F, et al. Microvasculature in angiotensin ii-dependent cardiac hypertrophy in the rat. Hypertension 1998; 32: 371-375.
72. Lemmens K, Segers VF, Demolder M, et al. Role of neuregulin-1/erbb2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 2006; 281: 19469-19477.
73. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/erbb signaling in cardiovascular physiology and disease: Implications for therapy of heart failure. Circulation 2007; 116: 954-960.
74. Hedhli N, Kalinowski A, Huang Q, et al. Endothelial neuregulin expression is essential for maintaining capillaries in the heart and preserving cardiac function. Circulation 2009; 120: S791b.
75. Sabino B, Lessa MA, Nascimento AR, et al. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: Intravital microscopy and histologic analysis. J Cardiovasc Pharmacol 2008; 51: 402-409.
76. Iivanainen E, Nelimarkka L, Elenius V, et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding egf-like growth factor. Faseb J 2003; 17: 1609-1621.
77. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 2007; 45 Suppl A: A25-A32.
78. Gao R, Zhang J, Cheng L, et al. A phase ii, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010; 55: 1907-1914.
79. Yan X, Morgan JP. Neuregulin1 as novel therapy for heart failure. Curr Pharm Des 2011; 17: 1808-1817.